AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03462329
Drug: Antibiotics (preferentially oral doxycycline 100 mg bid)
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with antibiotics for Lyme disease.
Trial: NCT01773798
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
Trial: NCT01025648
Drug: epinephrine inhalation aerosol, CFC propelled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
Trial: NCT01025648
Drug: E004 (epinephrine inhalation aerosol), 160 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
Trial: NCT01512355
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline_02mcg/kg/hr
Trial: NCT03785756
Drug: Ibuprofen 300 mg Oral Tablet
RxNorm normalized name: ibuprofen 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 300 mg tablets at Hours 0 and 12
Trial: NCT03785756
Drug: Ibuprofen 200 mg Oral Tablet
RxNorm normalized name: IBUPROFEN 200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 200 mg tablets at Hours 0, 8, and 16
Trial: NCT03785756
Drug: Placebo of PR tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets up to four times in 24 hours
Trial: NCT03785756
Drug: Placebo of IR tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets up to four times in 24 hours
Trial: NCT00871494
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
Trial: NCT01539902
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
Trial: NCT02192645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
Trial: NCT01430416
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00431067
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00475969
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00988429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet given QD
Trial: NCT03110640
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were given cyclophosphamide 500mg/m2/day on day -4.
Trial: NCT01074229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection
Trial: NCT01107717
Drug: metformin\pioglitazone\exenatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
Trial: NCT03536520
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Trial: NCT03369119
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01118429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
Trial: NCT01448993
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taking 250mg azithromycin 3 times per week in alternate days.
Trial: NCT01448993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03498456
Drug: Lansoprazole/Amoxicillin/Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
Trial: NCT00452322
Drug: Testosterone Substitution by Testosterone Undecanoate i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00370747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00463957
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00399945
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01082354
Drug: recombinant somatropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as per standard practice
Trial: NCT02259959
Drug: Single rising doses of BI 1744 CL, solution for oral inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01320683
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01320683
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01469429
Drug: chemoprevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive LBR lozenge PO
Trial: NCT02099656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
Trial: NCT02099656
Drug: Second Asthma Controller Medication
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
Trial: NCT01387464
Drug: ISV-303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% bromfenac in DuraSite dosed QD
Trial: NCT01387464
Drug: Bromday™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09% bromfenac dosed QD
Trial: NCT01642030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Trial: NCT04214808
Drug: Avodart Soft Capsule 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5mg
Trial: NCT00313963
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
Trial: NCT01378533
Drug: epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
Trial: NCT02444884
Drug: MLN8237
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02188745
Drug: 17B-estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-estrogen
Trial: NCT02861716
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds.
Trial: NCT01843920
Drug: standard post-operative topical drops
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
Trial: NCT00244556
Drug: Methotrexate plus ENBREL or ENBREL alone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02092909
Drug: IMO-8400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO-8400 at escalating dose levels by subcutaneous injection
Trial: NCT00118937
Drug: Placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
Trial: NCT00118937
Drug: Placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
Trial: NCT02625636
Drug: SAR438544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT02625636
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT04364035
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unit-dose placebo tablet delivered as two 3-mg placebo tablets
Trial: NCT03219788
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
Trial: NCT03219788
Drug: Remifentanil 0.1 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
Trial: NCT03219788
Drug: Remifentanil 0.2 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
Trial: NCT01782560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03152409
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
Trial: NCT00635323
Drug: Irinotecan plus capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
Trial: NCT01721109
Drug: EVG/COBI/FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/300 mg STR administered orally once daily with food
Trial: NCT00282386
Drug: MK0966; Rofecoxib / Duration of Treatment: 156 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00282386
Drug: Placebo/ Duration of Treatment: 156 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01009255
Drug: GSK239512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H3 Antagonist
Trial: NCT01009255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GSK239512
Trial: NCT01803945
Drug: AVE8112
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00472368
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04064840
Drug: IVF: Decapeptyl and hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
Trial: NCT01666210
Drug: Placebo Vehicle Punctum Plug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel punctum plug without dexamethasone
Trial: NCT04064840
Drug: FET: Decapeptyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
Trial: NCT04064840
Drug: IVF: hCG and normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
Trial: NCT04064840
Drug: FET: Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the day of FET, normal saline will be injected subcutaneously.
Trial: NCT03125161
Drug: HAI
RxNorm normalized name: THAIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI
Trial: NCT03125161
Drug: chemotherapy ± target therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy ± target therapy
Trial: NCT04625985
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
Trial: NCT02588027
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
Trial: NCT02588027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacy formulated placebo
Trial: NCT02653313
Drug: Parvovirus H-1 (H-1PV)
RxNorm normalized name: human parvovirus B19 virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu.
Trial: NCT00571519
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets matching rivoglitazone tablets administered orally, once daily
Trial: NCT00571519
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules for pioglitazone administered orally, once daily
Trial: NCT01596894
Drug: Azithromycin + Metronidazole
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
Trial: NCT01261793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Trial: NCT04031534
Drug: F-Miso PET scan coupled with MRI
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
Trial: NCT03839485
Drug: Endodontic treatment using Guedes-Pinto Paste
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
Trial: NCT03839485
Drug: Endodontic using Guedes-Pinto Paste without antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
Trial: NCT05060406
Drug: LY06006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
Trial: NCT00363090
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00363090
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04882956
Drug: intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolucizumab-Dbll intravitreal injection
Trial: NCT04882956
Drug: intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflipercept intravitreal injection
Trial: NCT02316821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01298219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, 0 mcg administered orally twice daily (BID)
Trial: NCT03196180
Drug: Topical Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravaginally
Trial: NCT03600506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
Trial: NCT00720161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01927484
Drug: 25 mg/week oral methotrexate tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active oral methotrexate drug
Trial: NCT01927484
Drug: 25mg/week oral placebo tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator oral drug
Trial: NCT03593187
Drug: Cal-1 (LVsh5/C46) drug product
RxNorm normalized name: Cal Gest Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
Trial: NCT01033123
Drug: BSI-201
RxNorm normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, 5.6 mg/kg
Trial: NCT01358201
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00604344
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02782273
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
Trial: NCT03386344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Trial: NCT06247267
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.
Trial: NCT01870297
Drug: LY3025876
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT01870297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT02634528
Drug: Julphar Insulin N (human isophane insulin)
RxNorm normalized name: insulin isophane Pen Injector [Novolin N]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational insulin: Julphar N (human isophane insulin), biosimilar
Trial: NCT02634528
Drug: Huminsulin® Basal (NPH, human isophane insulin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
Trial: NCT00490243
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no